Cargando…
Protective efficacy of inactivated reverse genetics based equine influenza vaccine candidate adjuvanted with Montanide(TM) Pet Gel in murine model
Equine influenza is a leading cause for respiratory illness in equines. Major control measures involve vaccination which requires continuous harmonization owing to antigenic drift. The present study focused on assessing the protective efficacy of an inactivated recombinant equine influenza virus (rg...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Japanese Society of Veterinary Science
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6943333/ https://www.ncbi.nlm.nih.gov/pubmed/31656240 http://dx.doi.org/10.1292/jvms.19-0399 |
_version_ | 1783484870147702784 |
---|---|
author | MATHEW, Manu Kurian VIRMANI, Nitin BERA, Bidhan Chandra ANAND, Taruna KUMAR, Ramesh BALENA, Venkataramireddy SANSANWAL, Rekha PAVULRAJ, Selvaraj SUNDARAM, Karthik VIRMANI, Meenakshi TRIPATHI, Bhupendra Nath |
author_facet | MATHEW, Manu Kurian VIRMANI, Nitin BERA, Bidhan Chandra ANAND, Taruna KUMAR, Ramesh BALENA, Venkataramireddy SANSANWAL, Rekha PAVULRAJ, Selvaraj SUNDARAM, Karthik VIRMANI, Meenakshi TRIPATHI, Bhupendra Nath |
author_sort | MATHEW, Manu Kurian |
collection | PubMed |
description | Equine influenza is a leading cause for respiratory illness in equines. Major control measures involve vaccination which requires continuous harmonization owing to antigenic drift. The present study focused on assessing the protective efficacy of an inactivated recombinant equine influenza virus (rgEIV) vaccine candidate adjuvanted with Montanide(TM) Pet Gel in murine model. The rgEIV was generated using reverse genetics by incorporating HA and NA segments from EIV/H3N8, clade 2-Florida sublineage in an A/WSN/33 /H1N1 backbone and inactivated by formalin. The vaccine was prepared by mixing inactivated rgEIV with Montanide(TM) Pet Gel adjuvant followed by intranasal inoculation into BALB/c mice intranasally. The immune responses and protective efficacy of the vaccine was evaluated by measurement of antibody titer, immunoglobulin subtyping, cytokines, clinical signs and pathological lesions after immunization and challenge with wild EIV. Serology and cytokine expression pattern indicated that the vaccine activated mixed Th1- and Th2-like responses of vaccine. Booster immunization stimulated strong antibody responses (HAI titre: 192 ± 28.6) at 42 days post immunization and the predominant antibody subtype was IgG1. Upregulation of interferon (IFN)-gamma, interleukin (IL)-12 and IL-2 levels indicates effective induction of Th1 type response. We found that vaccination has protected mice against equine influenza virus challenge as adjudged through a lack of nonappearance of visible clinical signs of disease, no loss of body weight loss, reduced pathology in the lungs and markedly reduced virus shedding from the respiratory tract. Therefore, we conclude that recombinant EIV vaccine candidate adjuvanted with Montanide(TM) Pet Gel could aid in quick harmonization of the vaccines through replacement of HA and NA genes for control of EIV outbreaks. |
format | Online Article Text |
id | pubmed-6943333 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | The Japanese Society of Veterinary Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-69433332020-01-08 Protective efficacy of inactivated reverse genetics based equine influenza vaccine candidate adjuvanted with Montanide(TM) Pet Gel in murine model MATHEW, Manu Kurian VIRMANI, Nitin BERA, Bidhan Chandra ANAND, Taruna KUMAR, Ramesh BALENA, Venkataramireddy SANSANWAL, Rekha PAVULRAJ, Selvaraj SUNDARAM, Karthik VIRMANI, Meenakshi TRIPATHI, Bhupendra Nath J Vet Med Sci Virology Equine influenza is a leading cause for respiratory illness in equines. Major control measures involve vaccination which requires continuous harmonization owing to antigenic drift. The present study focused on assessing the protective efficacy of an inactivated recombinant equine influenza virus (rgEIV) vaccine candidate adjuvanted with Montanide(TM) Pet Gel in murine model. The rgEIV was generated using reverse genetics by incorporating HA and NA segments from EIV/H3N8, clade 2-Florida sublineage in an A/WSN/33 /H1N1 backbone and inactivated by formalin. The vaccine was prepared by mixing inactivated rgEIV with Montanide(TM) Pet Gel adjuvant followed by intranasal inoculation into BALB/c mice intranasally. The immune responses and protective efficacy of the vaccine was evaluated by measurement of antibody titer, immunoglobulin subtyping, cytokines, clinical signs and pathological lesions after immunization and challenge with wild EIV. Serology and cytokine expression pattern indicated that the vaccine activated mixed Th1- and Th2-like responses of vaccine. Booster immunization stimulated strong antibody responses (HAI titre: 192 ± 28.6) at 42 days post immunization and the predominant antibody subtype was IgG1. Upregulation of interferon (IFN)-gamma, interleukin (IL)-12 and IL-2 levels indicates effective induction of Th1 type response. We found that vaccination has protected mice against equine influenza virus challenge as adjudged through a lack of nonappearance of visible clinical signs of disease, no loss of body weight loss, reduced pathology in the lungs and markedly reduced virus shedding from the respiratory tract. Therefore, we conclude that recombinant EIV vaccine candidate adjuvanted with Montanide(TM) Pet Gel could aid in quick harmonization of the vaccines through replacement of HA and NA genes for control of EIV outbreaks. The Japanese Society of Veterinary Science 2019-10-28 2019-12 /pmc/articles/PMC6943333/ /pubmed/31656240 http://dx.doi.org/10.1292/jvms.19-0399 Text en ©2019 The Japanese Society of Veterinary Science This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License. (CC-BY-NC-ND 4.0: https://creativecommons.org/licenses/by-nc-nd/4.0/) |
spellingShingle | Virology MATHEW, Manu Kurian VIRMANI, Nitin BERA, Bidhan Chandra ANAND, Taruna KUMAR, Ramesh BALENA, Venkataramireddy SANSANWAL, Rekha PAVULRAJ, Selvaraj SUNDARAM, Karthik VIRMANI, Meenakshi TRIPATHI, Bhupendra Nath Protective efficacy of inactivated reverse genetics based equine influenza vaccine candidate adjuvanted with Montanide(TM) Pet Gel in murine model |
title | Protective efficacy of inactivated reverse genetics based equine influenza
vaccine candidate adjuvanted with Montanide(TM) Pet Gel in murine
model |
title_full | Protective efficacy of inactivated reverse genetics based equine influenza
vaccine candidate adjuvanted with Montanide(TM) Pet Gel in murine
model |
title_fullStr | Protective efficacy of inactivated reverse genetics based equine influenza
vaccine candidate adjuvanted with Montanide(TM) Pet Gel in murine
model |
title_full_unstemmed | Protective efficacy of inactivated reverse genetics based equine influenza
vaccine candidate adjuvanted with Montanide(TM) Pet Gel in murine
model |
title_short | Protective efficacy of inactivated reverse genetics based equine influenza
vaccine candidate adjuvanted with Montanide(TM) Pet Gel in murine
model |
title_sort | protective efficacy of inactivated reverse genetics based equine influenza
vaccine candidate adjuvanted with montanide(tm) pet gel in murine
model |
topic | Virology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6943333/ https://www.ncbi.nlm.nih.gov/pubmed/31656240 http://dx.doi.org/10.1292/jvms.19-0399 |
work_keys_str_mv | AT mathewmanukurian protectiveefficacyofinactivatedreversegeneticsbasedequineinfluenzavaccinecandidateadjuvantedwithmontanidetmpetgelinmurinemodel AT virmaninitin protectiveefficacyofinactivatedreversegeneticsbasedequineinfluenzavaccinecandidateadjuvantedwithmontanidetmpetgelinmurinemodel AT berabidhanchandra protectiveefficacyofinactivatedreversegeneticsbasedequineinfluenzavaccinecandidateadjuvantedwithmontanidetmpetgelinmurinemodel AT anandtaruna protectiveefficacyofinactivatedreversegeneticsbasedequineinfluenzavaccinecandidateadjuvantedwithmontanidetmpetgelinmurinemodel AT kumarramesh protectiveefficacyofinactivatedreversegeneticsbasedequineinfluenzavaccinecandidateadjuvantedwithmontanidetmpetgelinmurinemodel AT balenavenkataramireddy protectiveefficacyofinactivatedreversegeneticsbasedequineinfluenzavaccinecandidateadjuvantedwithmontanidetmpetgelinmurinemodel AT sansanwalrekha protectiveefficacyofinactivatedreversegeneticsbasedequineinfluenzavaccinecandidateadjuvantedwithmontanidetmpetgelinmurinemodel AT pavulrajselvaraj protectiveefficacyofinactivatedreversegeneticsbasedequineinfluenzavaccinecandidateadjuvantedwithmontanidetmpetgelinmurinemodel AT sundaramkarthik protectiveefficacyofinactivatedreversegeneticsbasedequineinfluenzavaccinecandidateadjuvantedwithmontanidetmpetgelinmurinemodel AT virmanimeenakshi protectiveefficacyofinactivatedreversegeneticsbasedequineinfluenzavaccinecandidateadjuvantedwithmontanidetmpetgelinmurinemodel AT tripathibhupendranath protectiveefficacyofinactivatedreversegeneticsbasedequineinfluenzavaccinecandidateadjuvantedwithmontanidetmpetgelinmurinemodel |